Compare Jones Lang LaSalle Inc (JLL) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Jones Lang LaSalle Inc vs BIO-TECHNE Corp — how do they compare? Jones Lang LaSalle Inc trades at $303.6 (market cap $13.65B), while BIO-TECHNE Corp trades at $72.46 (market cap $11.37B). The key difference: Jones Lang LaSalle Inc is the larger of the two by market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Jones Lang LaSalle Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Jones Lang LaSalle Inc for 71 Days and BIO-TECHNE Corp for 63 Days on average.
| JLL | TECH | |
|---|---|---|
Market Cap | $13.65B | $11.37B |
Volume | 465,758 | 3,153,511 |
Sector | Real Estate | Health |
52-Week High | $392.79 | $72.61 |
52-Week Low | $280.16 | $43.31 |
Typical Hold Time | 71 Days | 63 Days |
Enterprise Value | $16.41B | $11.40B |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JLL trades at $296.66, down 2.29% today, with technical indicators showing bearish momentum despite strong fundamental performance. The company reported three consecutive quarterly earnings beats, with Q2 2026 EPS of $5.26 beating expectations by 15%. Revenue growth accelerated to $26.12 billion in 2025, while net income margin improved to 3.64%. Recent acquisitions and financing deals demonstrate continued expansion in key markets.
The stock presents a compelling value opportunity with a P/E of 14.23 and P/S of 0.52 below industry averages. Analyst consensus targets $450.50, implying 52% upside potential. Key risks include real estate market cyclicality and execution challenges in global expansion. Strong cash flow generation and institutional buying support the bullish fundamental case despite near-term technical weakness.
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal and strong institutional interest. Recent earnings show mixed results, beating in Q2 2026 but missing in Q1. The company maintains solid profitability with a 65.77% gross margin, though net income declined to $73.40M in 2025. Shareholders approved an acquisition by Merck KGaA at $73.00 per share, a key near-term catalyst.
Outlook is positive due to the pending acquisition, but risks include execution challenges and valuation concerns with a high P/E of 62.53. Analyst consensus is divided with 46% buy ratings, suggesting cautious optimism. The stock offers limited upside to the acquisition price, making it suitable for event-driven investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Jones Lang LaSalle Inc
Jones Lang LaSalle provides a wide range of real estate-related services to owners, occupiers, and investors worldwide, including leasing, property and project management, and capital markets advisory. JLL's investment management arm, LaSalle Investment Management, manages over $70 billion for clients across diverse public and private real estate strategies.
Read more on JLL →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
